Nuocheng Jianhua releases 2020 annual performance report and company progress

● In the United States, the first patient will complete the administration in early 2021
.

ICP-723

● A phase I clinical trial is being carried out in China to evaluate the safety, tolerability and PK characteristics of ICP-723 for the treatment of advanced solid tumors
.
In the phase I dose escalation study, two groups of patients (1 and 2 mg) have completed the administration, and no treatment-related serious adverse events (SAE) were found in all patients, and no dose-limiting toxicity (DLT) was observed
.
The dose of the third group of patients was increased to 3 mg, and NTRK gene fusion patients have been recruited for effectiveness evaluation
.

Nuocheng Jianhua also has a number of drug candidates at the IND preparation stage, and the company is actively advancing the IND application to enter the clinic
.

● In the field of autoimmune diseases, Nuocheng Jianhua owns ICP-332, ICP-488 and ICP-490
.
ICP-332 is a small molecule tyrosine kinase 2 (TYK2) inhibitor and will be used to treat many diseases such as psoriasis
.
ICP-488 is a small molecule inhibitor (JH2) of the pseudokinase domain of TYK2, used to treat diseases such as psoriasis and inflammatory bowel disease (IBD)
.
ICP-490 is an immunomodulator.
By combining with CRL4CRBN-E3 ligase complex, ICP-490 can induce the ubiquitination and degradation of transcription factors including Ikaros and Aiolos
.

● In terms of solid tumors, Nuocheng Jianhua owns ICP-189, ICP-033 and ICP-B03
.
ICP-189 is an allosteric inhibitor of SHP2 with good selectivity to other phosphatases
.
ICP-033 is a multi-kinase inhibitor mainly targeting Discoidin Domain Receptor 1 (DDR1) and Vascular Endothelial Growth Factor Receptor (VEGFR).
It is planned to be combined with immunotherapy and other targeted drugs to treat liver cancer, renal cell carcinoma, Colorectal cancer and other solid tumors
.
ICP-B03 is a prodrug of interleukin IL-15 that can be targeted for tumor release, which can target and change immune cells in the tumor microenvironment
.

● In terms of hematoma, Nuocheng Jianhua owns ICP-490 and ICP-248
.
ICP-248 is a selective inhibitor of B-cell lymphoma 2 (BCL-2)
.
ICP-248 is planned to be combined with abutinib to treat AML, ALL, FL, CLL, DLBCL and other hematological malignancies
.

The latest developments of other companies

● Introduce strategic investment
.
On February 3, 2021, Hillhouse Capital became a strategic investor in Nuocheng Jianhua, and Vivo Capital continued to increase its holdings
.
The biomedical industry needs continuous innovative R&D and capital support
.
Through more capital support, Nuocheng Jianhua is committed to developing more high-quality innovative drugs to benefit more patients
.

● Globalization
.
Nuocheng Jianhua appointed Dr.
Xiangyang Zhang, who has extensive clinical experience, as the company's chief medical officer in early March 2021.
His office is in the United States, further demonstrating Nuocheng Jianhua's commitment to global development
.

● Improve business development (BD) capabilities
.
In October 2020, Nuocheng Jianhua appointed Dr.
Manish Tandon, who has extensive experience in the BD field, as the vice president of business development.
His office is in the United States, further enhancing the company's strength in external business development and cooperation
.

"After five years of solid and rapid development, Nuocheng Jianhua has established a rich product pipeline
.
At the same time, we have maintained financial stability and provided a good guarantee for business development," said Dr.
Cui Jisong
.

Financial performance summary

● The company's revenue and other income will increase from 105.
7 million yuan in 2019 to 272.
7 million yuan in 2020
.
With the approval of obritinib, the company's revenue sources will be more diversified in 2021
.

● The company's cash and bank balances increased from 2.
291.
8 billion yuan in 2019 to 3.
969.
6 billion yuan in 2020
.

● The company's R&D expenditure will increase from 213.
1 million yuan in 2019 to 402.
8 million yuan in 2020
.

● The company's loss decreased from RMB 2.
140.
4 billion in 2019 to RMB 464.
3 million in 2020, including a loss of RMB 1.
814 billion from changes in the fair value of convertible redeemable preferred shares (converted to ordinary shares after the initial public offering) in 2019 ( The loss in 2020 is 141.
6 million yuan)
.

(Note: The currency is Renminbi, and Nuocheng Jianhua’s financial year refers to January 1 to December 31 of a certain year)

About Nuocheng Jianhua

Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) is a commercialized biomedical high-tech company, focusing on the development of a class of new drugs in the treatment of malignant tumors and autoimmune diseases, suitable for the high incidence of lymphoma in Chinese patients , Liver cancer, cholangiocarcinoma, urothelial cancer and other malignant tumors and autoimmune diseases
.
Several new drug products are currently in commercialization, clinical and pre-clinical research and development stages
.
The company has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey and Boston
.